Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1999-2-4
pubmed:abstractText
Interleukin (IL)-3, IL-5 and granulocyte macrophage colony-stimulating factor (GM-CSF) prolong the survival of eosinophils, which are conspicuous in asthmatic airways, but it is still controversial which one plays a major role in enhancing the survival of eosinophils in asthmatic airways. The role of these cytokines in airway eosinophilia was investigated using bronchoalveolar lavage (BAL) fluids from 11 symptomatic and nine asymptomatic patients with asthma and eight normal subjects. Eosinophil survival-enhancing activity (ESEA) was measured by a numerical change in viable eosinophils isolated from the peripheral blood of atopic patients and cultured with BAL fluids. ESEA was characterized by neutralization with antibodies to IL-3, IL-5 and/or GM-CSF. The differential count of BAL cells was achieved using Diff-Quik stain. T-cell subsets and activated T-cells were analysed by flow cytometry with dual stain using monoclonal antibodies to CD3, CD4, CD8 and CD25. ESEA was detected in eight of 11 BAL fluids of symptomatic asthma, but not in those of normal controls or asymptomatic asthmatics. In six symptomatic asthmatics, the mean percentage of inhibition in ESEA by anti-GM-CSF was higher than that of anti-IL-5 as well as anti-IL-3 (p<0.05). A mixture of antibodies to IL-3, IL-5 and GM-CSF totally inhibited the ESEA in four cases. The ESEA correlated with the percentage of eosinophils (p<0.05) and that of CD25(+)CD4 lymphocytes (p<0.05) of BAL cells. In conclusion, granulocyte macrophage colony-stimulating factor, rather than interleukin-3 or -5, is associated with eosinophil survival-enhancing activity inside the airways of symptomatic asthmatics. The activation of CD4 lymphocytes is related to the elevation of such activity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0903-1936
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
872-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9817161-Adult, pubmed-meshheading:9817161-Aged, pubmed-meshheading:9817161-Asthma, pubmed-meshheading:9817161-Bronchial Provocation Tests, pubmed-meshheading:9817161-Bronchoalveolar Lavage Fluid, pubmed-meshheading:9817161-Cell Survival, pubmed-meshheading:9817161-Cells, Cultured, pubmed-meshheading:9817161-Dose-Response Relationship, Drug, pubmed-meshheading:9817161-Eosinophils, pubmed-meshheading:9817161-Female, pubmed-meshheading:9817161-Flow Cytometry, pubmed-meshheading:9817161-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:9817161-Humans, pubmed-meshheading:9817161-Leukocyte Count, pubmed-meshheading:9817161-Male, pubmed-meshheading:9817161-Middle Aged, pubmed-meshheading:9817161-Reference Values, pubmed-meshheading:9817161-Respiratory Function Tests, pubmed-meshheading:9817161-Statistics, Nonparametric, pubmed-meshheading:9817161-T-Lymphocytes
pubmed:year
1998
pubmed:articleTitle
Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways.
pubmed:affiliation
Dept of Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't